Sonnet Biotherapeutics Holdings Stock Current Valuation
| SONN Stock | USD 2.63 0.14 5.05% |
Valuation analysis of Sonnet Biotherapeutics helps investors to measure Sonnet Biotherapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 29th of November 2024, Enterprise Value Over EBITDA is likely to grow to -11.81. In addition to that, Enterprise Value Multiple is likely to grow to -11.81. Fundamental drivers impacting Sonnet Biotherapeutics' valuation include:
Price Book 0.8415 | Enterprise Value -1.2 M | Enterprise Value Ebitda (0.21) | Price Sales 39.4238 | Enterprise Value Revenue 35.9059 |
Fairly Valued
Today
Please note that Sonnet Biotherapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Sonnet Biotherapeutics is based on 3 months time horizon. Increasing Sonnet Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sonnet Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sonnet Stock. However, Sonnet Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.63 | Real 2.52 | Target 73.0 | Hype 2.63 | Naive 3.67 |
The intrinsic value of Sonnet Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sonnet Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sonnet Biotherapeutics Holdings helps investors to forecast how Sonnet stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sonnet Biotherapeutics more accurately as focusing exclusively on Sonnet Biotherapeutics' fundamentals will not take into account other important factors: Sonnet Biotherapeutics Holdings Company Current Valuation Analysis
Sonnet Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sonnet Biotherapeutics Current Valuation | (1.2 M) |
Most of Sonnet Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonnet Biotherapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sonnet Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Sonnet Biotherapeutics is extremely important. It helps to project a fair market value of Sonnet Stock properly, considering its historical fundamentals such as Current Valuation. Since Sonnet Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sonnet Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sonnet Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Sonnet Current Valuation Historical Pattern
Today, most investors in Sonnet Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sonnet Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sonnet Biotherapeutics current valuation as a starting point in their analysis.
Sonnet Biotherapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sonnet Biotherapeutics Holdings has a Current Valuation of (1.2 Million). This is 100.01% lower than that of the Biotechnology sector and 100.03% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
Sonnet Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonnet Biotherapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonnet Biotherapeutics could also be used in its relative valuation, which is a method of valuing Sonnet Biotherapeutics by comparing valuation metrics of similar companies.Sonnet Biotherapeutics is currently under evaluation in current valuation category among its peers.
Sonnet Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sonnet Biotherapeutics from analyzing Sonnet Biotherapeutics' financial statements. These drivers represent accounts that assess Sonnet Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sonnet Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 36.3M | 193.5M | 118.9M | 51.0M | 23.8M | 34.4M | |
| Enterprise Value | 46.1M | 186.5M | 91.4M | 48.2M | 21.7M | 43.8M |
Sonnet Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonnet Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonnet Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Sonnet Fundamentals
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (219.69) % | ||||
| Current Valuation | (1.2 M) | ||||
| Shares Outstanding | 837.66 K | ||||
| Shares Owned By Insiders | 4.22 % | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 35.2 K | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 39.42 X | ||||
| Revenue | 147.81 K | ||||
| Gross Profit | (21.09 M) | ||||
| EBITDA | (18.72 M) | ||||
| Net Income | (18.83 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 203.91 K | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 1.10 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (21.34 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 240.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 2.2 M | ||||
| Total Asset | 5.43 M | ||||
| Retained Earnings | (110.24 M) | ||||
| Working Capital | (786.37 K) | ||||
| Net Asset | 5.43 M |
About Sonnet Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonnet Biotherapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonnet Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock: Check out Sonnet Biotherapeutics Piotroski F Score and Sonnet Biotherapeutics Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.